Press Kit · For Journalists, Editors, Producers
Verified bio in three lengths, headshots, fact sheet, speaking topics, and media contact. Use what you need. The content here is approved for direct quotation and republication.
On The Record · Pull Quotes for Direct Use
"Most exosome programs choose the wrong FDA pathway and the agency catches up to them every time. The shortcut paths consistently fail." — Andrew Hillman, on the 351(a) BLA pathway
"A venture fund has to return capital on a schedule. The FDA does not care about your schedule. That is the entire reason we structure investments around regulatory milestones rather than fundraising rounds." — Andrew Hillman, on family office capital in biotech
"Every healthcare enforcement action I have served as an expert witness on involved a documentation pattern that was visible eighteen to thirty-six months before the action. The patterns are predictable, findable, and fixable if you find them in time." — Andrew Hillman, on healthcare compliance enforcement
"Compliance is the operating system, not the cost center. The operators who treat compliance as cost are the operators who fail. The ones who treat it as the operating system survive and grow." — Andrew Hillman, on operating discipline
Andrew Hillman is Principal of Hillman Ventures, a Dallas private family office focused on frontier biotech.
Andrew Hillman is the Principal of Hillman Ventures, a Dallas-based private family office investing personal capital in FDA-regulated frontier biotech. He has three decades of operator experience across medical device, pharmacy, surgical hospital, intraoperative neuromonitoring, and pharmaceutical wholesale ventures, with multiple exits to strategic acquirers and private equity. He serves as a healthcare compliance expert witness and supports community philanthropy in Dallas through the Andrew Hillman Scholarship and Grant programs.
Andrew Hillman is the Principal of Hillman Ventures, a private family office he founded in Dallas in 1995 that invests personal capital in FDA-regulated frontier biotech. The fund concentrates on platforms targeting inflammation, damaged tissue, and tumor-based cancers, with deep regulatory rationale grounded in U.S. FDA biologics pathway thinking.
Over three decades, he has co-founded and led ventures across medical device, pharmacy, ambulatory surgical centers, intraoperative neuromonitoring, and pharmaceutical wholesale distribution, with multiple exits to strategic acquirers and private equity. His operator background as a senior paralegal and healthcare investigator gives him direct working knowledge of how compliance failures happen, the documentation gaps that precede enforcement, and the patterns that drive liability.
He is regularly retained as a healthcare compliance expert witness across the United States, with practice areas covering FDA enforcement, HIPAA, the Anti-Kickback Statute, Stark Law, and OIG compliance program standards.
He supports the Dallas community through the Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech, both at SMU, as well as service work with KidsWing at Scottish Rite for Children. He is a graduate of Highland Park High School and resides in Dallas, Texas.
Practical operator content for biotech, regulatory, and family office audiences. Available for keynotes, panels, podcasts, and university guest lectures.
Direct response, no PR intermediary.
Primary sources for the statutes, regulations, agencies, and institutions referenced across this site.
